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How the immune system attacks medulloblastoma (MB) tumors effectively is unclear,
although natural killer (NK) cells play an important role in immune defense against tumor
cells. Interactions between receptors on NK cells and ligands expressed by tumor cells are
critical for tumor control by immunotherapy. In this study, we analyzed tumor samples from
54 MB patients for expression of major histocompatibility complex class I-related chains
A (MICA) and UL16 binding protein (ULPB-2), which are ligands for the NK group 2 mem-
ber D activatory receptor (NKG2D).The percentage of MICA and ULBP-2 positive cells was
higher than 25% in 68% and 6% of MB patients, respectively. A moderate-high intensity of
MICA cytoplasmic staining was observed in 46% MB patients and weak ULBP-2 staining
was observed in 8% MB patients. No correlation between MICA/ULBP-2 expression and
patient outcome was found. We observed that HTB-186, a MB cell line, was moderately
resistant to NK cell cytotoxicity in vitro. Blocking MICA/ULBP-2 on HTB-186, and NKG2D
receptor on NK cells increased resistance to NK cell lysis in vitro. However, HLA class
I blocking on HTB-186 and overnight incubation with IL-15 stimulated NK cells efficiently
killed tumor cells in vitro. We conclude that although NKG2D/MICA-ULBP-2 interactions
have a role in NK cell cytotoxicity against MB, high expression of HLA class I can pro-
tect MB from NK cell cytotoxicity. Even so, our in vitro data indicate that if NK cells are
appropriately stimulated, they may have the potential to target MB in vivo.
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INTRODUCTION
Medulloblastoma (MB) is a highly aggressive pediatric primitive
neuroectodermal tumor usually located in the posterior fossa.
Current treatment for MB consists of a combination of surgi-
cal resection, systemic multidrug chemotherapy, and craniospinal
radiation (Von Hoff and Rutkowski, 2012). Up to 75% of patients
with average-risk MB with localized disease, who undergo com-
plete surgical resection and are older than 3 years old, can achieve
complete and persistent remission although long-term sequels
may occur (Douglas et al., 2004). In contrast, in patients with high-
risk MB with metastatic disease, large residual tumors, relapsing
disease and of a young age have a poor prognosis (Pérez-Martínez
et al., 2004; Butturini et al., 2009).
Knowledge of the molecular characteristics of MB has increased
during recent years (Leary and Olson, 2012). An understanding of
the growth control mechanisms involved in MB development has
allowed a better classification and development of target therapies
(Huse and Holland, 2010). Many signaling pathways have been
identified and numerous anticancer drugs have been designed to
target specific proteins in these pathways. However, minimal anti-
tumor activity has been reported (Fouladi et al., 2007; Rossi et al.,
2008). Although numerous novel immunotherapy approaches are
being explored, the dysfunction of patients T cells and the lack of
tumor-specific targets for cytotoxic T lymphocytes have limited
specific immune cell therapies (Sonabend et al., 2012). Although
there has not been any clear clinical success (Salmaggi et al., 1994;
Silvani et al., 1994; Sankhla et al., 1996), recent in vitro studies
have demonstrated that natural killer (NK) cells are able to lyse
MB cell lines (Castriconi et al., 2007). Because NK cells play a
major role in the immune defense against tumors, they are good
candidates for new immunotherapeutic approaches (Geller and
Miller, 2011). The NK cell antitumor effect is controlled through
the balance of signals mediated by activating and inhibitory recep-
tors found on each NK cell. Tumor transformation down-regulates
HLA class I expression, ligands to NK inhibitory receptors, and
up-regulates ligands for NK activating receptors, and results in
NK cell-mediated tumor lysis. MB cell lines express specific lig-
ands that trigger NK activating receptors and thus are susceptible
to NK-mediated cytotoxicity (Castriconi et al., 2007). Major histo-
compatibility complex class I-related chain A (MICA) and UL16
binding protein 2 (ULBP-2) are tumor cell surface ligands that
bind NK cell activating receptor NKG2D, and are prevalent in
malignant brain tumors (Friese et al., 2003; Castriconi et al., 2007;
Geller and Miller, 2011). Interactions between NKG2D receptors
on the surface of NK cells and their ligands (NKG2DL) on tumor
cells has been proposed as critical for NK cell cytotoxicity against
tumor cell lines, but also primary tumors (Friese et al., 2003; Kloess
et al., 2010; Bae et al., 2012; Pérez-Martínez et al., 2012).
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In this study, we show high expression of MICA on primary MB
cells and the important role of NKG2D/NKG2DL for NK cell cyto-
toxicity using HTB-186, a MB cell line. However, high expression
of HLA class I on MB cells cause them to become resistant to NK
cytotoxicity. We also demonstrate that blocking HLA class I on MB
cells and/or IL-15 stimulated NK cells can overcome the inhibitory
effect mediated by HLA class I overexpression on tumor cells.
MATERIALS AND METHODS
Our local Ethics Committee approved this study protocol and all
patients’ guardians gave their informed consent to this study.
PATIENTS AND CLINICAL CARE AND EVALUATION
Between 1990 and 2010, 54 MB patients were diagnosed and
treated at our institution (Table 1). Mean age at diagnosis was
6.5± 4.2 years (26% patients were younger than 3 years old). Gen-
der percentages were 59% male and 41% female. MB histological
analysis demonstrated the following classifications: 74% classi-
cal, 22% nodular, and 4% anaplastic. Metastasis at diagnosis was
present in 32% of patients. Neurosurgery complete debulking was
performed in 47% patients. Radiotherapy was performed in 82%
of the patients. High-dose chemotherapy and autologous stem cell
rescue was performed in 33% of patients. MB relapses occurred in
37% of patients.
ANTIBODIES AND FLOW CYTOMETRY ANALYSIS
The following fluorochrome-labeled monoclonal antibodies
(mAbs) against human antigens were obtained from R&D Sys-
tems (Minneapolis, MN, USA): MICA-PE, ULBP-1-PE, ULBP-
2-APC, ULBP-3-PE, and ULBP-4-PerCp-Cy5. Fluorochrome-
labeled mAbs against MICA/MICB were obtained from Biole-
gend Inc. (San Diego, CA, USA). Fluorochrome-labeled mAb
against HLA-ABC-PE was obtained from Becton Dickinson,
Franklin Lakes, NJ, USA. Mean fluorescent intensity for MICAB,
MICA, ULBP-1, ULBP-2, ULBP-3, and ULBP-4 was determined
in NB1691, K562, HTB-185, HTB-186, and HTB-187 cell lines
by multiparametric flow cytometry (Becton Dickinson, FAC-
SCanto II).
The mouse IgG2A isotype antibody and mouse anti-human
IgG2A MICA monoclonal antibody were purchased from R&D
Systems. The anti-HLA class I antibody used in blocking exper-
iments, W6/32 IgG2a, was kindly provided by Dr. S. Stevanovic
(Tubingen University, Germany). The mouse IgG2A anti-human
ULPB2 monoclonal antibody and anti-NKG2D IgG1 antibody
were purchased from Abcam (Cambridge, UK). All mAbs were
used at a final concentration of 10µg/ml, except for anti-HLA
class I that we used 20µg/ml.
IMMUNOHISTOCHEMISTRY
Specimens of pediatric tumors from 54 children with MB
were included on tissue microarray and analyzed as previously
described (Pérez-Martínez et al., 2012). Briefly, 3µm tissue
sections were paraffin-embedded for 30 min then put into a PT
Link (Dako) to conduct the pre-treatment processes of deparaf-
finization, rehydration, and epitope retrieval for 2 h. After that, the
slides were loaded on to an Autostainer (Dako) where the tissue
was blocked for endogenous peroxidase and stained using antibod-
ies against MICA (1:10, R&D Systems) and ULBP-2 (1:50, R&D
Systems). The Envision Flex (secondary antibody) and immun-
odetection system diaminobenzidine was used. The level of MICA
and ULBP-2 expression was assessed by the intensity of cytoplas-
mic staining as follows: (0 none, 1+ weak, 2+ moderate, and 3+
strong) and the percentage of positive cells (<25, 25–50, 50–75,
and >75%). Pancreas carcinoma served as a positive control for
ULBP-2 (Chen et al., 2008) and normal breast epithelium as a
positive control for MICA (Chang et al., 2011).
CYTOTOXICITY ASSAYS AND CELL LINES
The cytotoxicity of NK cells was monitored using a conven-
tional 2-h europium-TDA release assay (Perkin-Elmer Wallac,
Table 1 | Patient characteristics.
n % Overall survival P
Patient numbers (1990–2010) 54
Patient numbers (1990–2000/2001–2010) 24/30 44/54 ns
Age (years) 6.5±4.2
Age (<3/>3 years) 14/40 26/74 42±1/53±1 ns
Sex (male/female) 32/22 59/41 54±1/43±1 ns
Histology (classic/nodular/anaplastic) 39/11/2 74/22/4 46±1/68±1/50±3 ns
Resection: CR/PR 25/28 47/53 62±1/40±1 0.05
Metastasis (no/yes) 34/16 68/32 56±1/30±1 0.05
Radiotherapy (yes/no) 40/9 82/18 60±1/11±1 0.000*
Relapse (yes/no) 18/31 37/63 13±1/69±1 0.001*
HDCT (yes/no) 15/31 33/67 29±1/57±1 ns
Status (CR/PR/dead) 22/4/22 46/8/46
Follow up (months) 60.0±2.6
Survival (1990–2000/2001–2010) 50±7 (52±1/40±1) ns
Data are expressed as mean±SEM. NS: no significance; CR: complete remission, PR: partial remission; HDCT: high dose chemotherapy and autologous stem cell
rescue.*Significance at multivariate analysis.
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Turku, Finland) as described previously (Blomberg et al., 1995).
Fresh peripheral blood mononuclear cells (PBMCs) obtained
from healthy volunteers were used as effector cells. K562 (ery-
throleukemia cell line, ATCC), HTB-186 (a MB cell line kindly
provided by Dr. P. Sánchez Gómez, Instituto de Salud Carlos III,
Madrid, Spain), and NB1691 (neuroblastoma cell line, kindly pro-
vided by Dr. A. Davidoff, St. Jude’s Children’s Research Hospital,
Memphis, TN, USA) were used as the target cells. In brief, target
cells were labeled with a fluorescence-enhancing ligand (BATDA).
This hydrophobic ligand quickly penetrates the cell membrane.
Within the cell, hydrolysis of ester bonds results in the ligand
becoming hydrophilic and therefore unable to pass through the
cell membrane. Cytolysis, however, results in the release of the
ligand and ultimately a reaction of the ligand with the europium
to form a stable, fluorescing chelate, which was evaluated fluoro-
metrically (Infinite F200 reader TECAN Group Ltd., Männedorf,
Switzerland). The number of NK cells was calculated by multiply-
ing the lymphocyte counts to the percentage of CD3−CD56+ NK
cells. The following formulas were used to calculate spontaneous
and specific cytotoxicity:
% Specific release = (experimental release− spontaneous release)
/
(
maximum release− spontaneous release)× 100.
% Spontaneous release = (spontaneous release− background)
/
(
maximum release− background)× 100.
IL-15 STIMULATED NK CELLS AND ANTIBODY BLOCKING EXPERIMENTS
Fresh PBMCs from healthy controls were stimulated overnight
with 25 ng/ml IL-15 (R&D Systems). Cultures were grown in
complete culture medium (RPMI 1640 supplemented with 10%
of heat-inactivated fetal bovine serum, 100 IU/ml penicillin,
100 ng/ml streptomycin, and 2 mM/l-glutamine) in a humidified
atmosphere of 5% CO2 and 95% air.
HTB-186 cell line was incubated with mouse IgG2A isotype
antibody, mouse anti-human MICA monoclonal IgG2A antibody,
anti-HLA class I IgG2A antibody, and mouse anti-ULPB-2 mono-
clonal IgG2A antibody for 2 h at 37˚C. PBMCs were incubated
with NKG2D IgG1 antibody for 30 min at room temperature,
and then washed twice in fresh complete medium. Following this,
cytotoxicity was measured as described above.
STATISTICAL ANALYSIS
Data was analyzed during August 2012. Results are given as
means± standard error, unless otherwise indicated. Significance
levels were determined by Student t -test analysis. P values of
0.05 or less were considered significant. Overall survival (OS)
was analyzed using Kaplan–Meier test and the log-rank test for
univariate analysis. The correlation between the magnitude of the
increase in NK cell cytotoxicity and NKG2DL expression on tumor
cell lines was determined by Pearson’s method, setting statistical
significance at P < 0.05.
RESULTS
PATIENTS AND OUTCOME
Between 1990 and 2010, 54 MB patients were diagnosed and
treated at our institution (Table 1). With a median of 60 months,
OS was 50± 7%. Univariate analysis demonstrated that quality
of resection, metastasis at diagnosis, radiotherapy, and relapse
impacted on OS. Multivariate analysis showed radiotherapy and
relapses impacted on OS.
IMMUNOHISTOCHEMISTRY
Of the MB patients, 46% demonstrated strong positive MICA
expression (38% moderate and 8% high) (Table 2). Weak expres-
sion was observed in 42% MB patients and 12% showed no MICA
positive staining. A total of 92 and 8% MB patients had either none
or weak ULBP-2 positive staining, respectively. A total of 62% MB
patients showed extensive expression of MICA, and of these 24%
had 50–75% MICA positive cells and 38% had>75% MICA pos-
itive cells. A total of 38% MB patients showed low expression of
MICA, where 6% had 25–50% MICA positive cells and 32% had
<25% MICA positive cells.
The percentage of ULPB-2 immunoreactivity in most MB
patients was <25%. Values between 25–50% were present in 6% of
patients (Figures 1A–D). MICA and ULBP-2 expression did not
have an impact on OS (Figures 1E,F). Thus, approximately 50%
of the samples had high MICA expression on a high percentage of
tumor cells and most samples had no ULBP-2 expression.
SURFACE EXPRESSION OF NKG2DLs ON TUMOR CELL LINES
Cell surface expression of NKG2DLs on tumor cell lines was
assessed by FACS analysis. Mean fluorescence intensity ratio was
determined by the fold-increase over isotype control using mouse
mAbs. The HTB-186 tumor cell line expressed the highest lev-
els of HLA class I, MICA, ULBP-2, ULBP-3 and the lowest
NKG2DLs/HLA class I ratio (Table 3 and Figure 2).
NK CELL CYTOTOXICITY AND BLOCKING EXPERIMENTS
Because from MB cell lines, HTB-186 expressed the highest lev-
els of ligands for NK cell receptors, we chose it from MB cell
lines, for cytotoxicity experiments. We observed HTB-186 cell line
was the most resistant cell line to resting NK cell cytotoxicity (26,
19, 16, 10% vs. 50, 34, 32, 31% on K562 and 42, 29, 19, 14% in
NB1691 at ratio 8/4/2/1:1, respectively). To investigate the impor-
tance of NKG2D-MICA/ULBP-2 interactions in MB patients we
examined in vitro NK cytotoxicity after blocking NKG2D recep-
tor on NK cells and blocking MICA and ULBP-2 on HTB-186
Table 2 | MICA/ULBP-2 positive cells and intensity of cytoplasmic
staining by immunohistochemistry on medulloblastoma tumors.
Positive cells n (%)
<25 25–50 50–75 >75
MICA 16 (32) 3 (6) 12 (24) 19 (38)
ULBP-2 47 (94) 3 (6) 0 (0) 0 (0)
Intensity of cytoplasmic staining n (%)
None Weak Moderate High
MICA 6 (12) 21 (42) 19 (38) 4 (8)
ULBP-2 46 (92) 4 (8) 0 (0) 0 (0)
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FIGURE 1 | MICA and ULBP-2 staining in MB. (A) MICA negative
staining in a sample of MB; (B) MICA high positive staining in a sample
of MB; (C) ULBP-2 negative staining in a sample of MB; (D) ULBP-2
weak staining in a sample of MB. Magnification×200 for all samples.
Impact of (E) MICA expression (%>50%, n= 31 vs. %<50%, n=19
and intensity cytoplasmic staining, none/weak, n=27, vs.
moderate/high, n=23); and (F) ULPB-2 expression (%>25%, n= 3 vs.
%<25%, n=47 and intensity of cytoplasmic staining, none, n=46,
vs. weak, n=4) for overall survival. n/w, none/weak; m/h,
moderate/high.
Table 3 | Cell surface expression of HLA-I and NKG2D ligands and NKG2D ligands/HLA-I ratio on medulloblastoma cell lines (HTB-185, HTB-186,
HTB-187), neuroblastoma cell line (NB1691) and erythroleukaemia cell line (K562) measured by mean fluorescence intensity (MFI).
Ligands HTB-185 HTB-186 HTB-187 NB1691 K562 Ligands HTB-185 HTB-186 HTB-187 NB1691 K562
HLA-I 1.50 28.57 1.34 1.83 1.88 MICA/HLA-I 2.21 0.52 1.12 3.50 6.07
MICA 5.66 14.96 1.98 6.39 11.44 MICAB/HLA-I 3.78 0.50 1.48 2.50 7.29
MICAB 3.31 14.23 1.49 4.57 13.75 ULBP-1/HLA-I 3.15 0.41 1.57 4.44 7.51
ULBP-1 4.73 11.72 2.10 8.11 14.16 ULBP-2/HLA-I 1.98 1.13 1.03 4.95 8.54
ULBP-2 2.97 32.42 1.37 9.04 16.10 ULBP-3/HLA-I 2.89 0.36 1.28 2.17 2.58
ULBP-3 4.33 10.37 1.72 3.96 4.85 ULBP-4/HLA-I 1.82 0.12 1.07 2.00 2.84
ULBP-4 2.73 3.34 1.43 3.65 5.34
cell line. NKG2D blocking decreased NK cell cytotoxicity twofold
and blocking MICA and ULBP-2 decreased cytotoxicity 1.5- and
1.2-fold when compared with groups using resting NK cells and
IgG2A, respectively. IL-15 stimulated NK cells increased cytotox-
icity twofold when compared with resting NK cells, however the
effect was similar to observed by IgG2A control. Moreover, block-
ing HLA class I on tumor cells increased NK cell cytotoxicity 3.4-
and 2-fold when compared with groups using resting NK cells
and IgG2A, respectively. Blocking HLA class I on tumor cells and
IL-15 stimulated NK cells increased cytotoxicity 3.7- and 2.1-fold
when compared with groups using resting NK cells and IgG2A,
respectively (Figure 3).
NK CELL CYTOTOXICITY AND BLOCKING EXPERIMENTS AND SURFACE
EXPRESSION OF NKG2DL/HLA CLASS I RATIO ON TUMOR CELL LINES
A positive correlation analysis between MICA/HLA class I,
ULBP-1/HLA class I and ULBP-4/HLA class I expression
and resting NK cell cytotoxicity was found (Pearson> 98%
and P < 0.05). In addition, a positive correlation between
MICB/HLA class I expression and IL-15 stimulated NK cells
was observed (Pearson> 99% and P < 0.05). Finally, a pos-
itive correlation between ULBP-1/HLA class I, ULBP-3/HLA
class I and ULBP-4/HLA class I expression and NKG2D block-
ing NK cells was found (Pearson> 99% and P < 0.05). No
significant correlations were found when we compared NK
cytotoxicity and HLA class I expression or NKG2L alone.
These findings suggest that the NKG2DL/HLA class I ratio
predicts NK cell cytotoxicity better than NKG2DL expression
alone.
DISCUSSION
This study investigated the potential role of NK cell immunother-
apy for MB based on the engagement of NKG2D receptor
by MICA/ULBP-2 ligands. We demonstrated that NKG2DLs,
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FIGURE 2 | Medulloblastoma cell lines, (HTB-185, HTB-186 MB, HTB-187), mean fluorescence intensity (MFI) was determined by multiparametric flow
cytometry (Becton Dickinson, FACSCanto II) for HLA-I expression and ligands for the NKG2D activating receptor.
FIGURE 3 | HTB-186 MB cell line susceptibility to: resting NK cells, IL-15
stimulated NK cells, NKG2D, MICA, ULBP-2 and HLA class I blocking
experiments at different effector target (E/T) ratio. Blocking MICA, ULBP-2
on HTB-186 cells and NKG2D on NK cells reduced NK cell mediated
cytotoxicity. HLA class I blocking on HTB-186 cells and IL-15 stimulated NK
cells increased NK cell mediated cytotoxicity.
especially MICA, expressed by MB primary tumors and ULPB-2
on HTB-186 cell line, were overexpressed. Despite MICA and
ULBP-2 overexpression, NK cell cytotoxicity was not as high as
we expected when NK cells were incubated with HTB-186. How-
ever, we observed a decrease in NK cell cytotoxicity when we
blocked NKG2D/MICA-ULBP-2 interactions. This suggests that
although NK cell cytotoxicity against MB is low, it is maintained
by NKG2D/MICA-ULBP-2 interactions. In addition, high HLA
class I expression on MB cells blocked NK cell cytotoxicity medi-
ated by NKG2DL, and blocking HLA class I on HTB-186 cells
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increased NK cell cytotoxicity. These data are in agreement with
results reported in glioma cell lines (Friese et al., 2003). However,
our data contrast with the high susceptibility of other MB cell lines
to NK cell cytotoxicity and the suggested major role of DNAM-
1 and NKG2D receptors (Castriconi et al., 2007). Although NK
cell triggering mediated by NKG2D-NKG2DL interactions have
been proposed as critical for NK cell cytotoxicity against most
pediatric malignancies we hypothesized a determinant role for the
inhibitory signals derived from HLA class I expression on tumor
cells. However, HLA class I expression in many cancers and MB
is heterogeneous, reflecting the status of the original cell before
transformation (Smith et al., 2011). Malignant transformation
may be associated with abnormalities in HLA class I expression
and in major histocompatibility complex class I-related molecules
(Raffaghello et al., 2007). Consequently, we observed that suscep-
tibility to NK cell cytotoxicity depends on NKGD2L/HLA class
I expression, and higher or lower ratios correspond to higher or
lower NK cytotoxicity.
High expression of NKGD2Ls has been described for other
brain malignant tumors. However, in parallel, they also had
increased HLA class I expression (Friese et al., 2003), which may
allow tumor cells escape NK cell immunosurveillance. Further-
more, the high expression of HLA class I may contribute to a more
malignant phenotype of MB by activation of ERK1/2 and result in
a poor prognosis (Raffaghello et al., 2007; Smith et al., 2009; Smith
et al., 2011). Because the brain lacks specific brain-associated
lymphoid tissue, tumor antigens elicit transient innate inflam-
matory immune responses, such as those mediated by NK cells,
but no adaptive immunity (Smith et al., 2011).
Interestingly, NK cell stimulation with IL-15 circumvented the
ability of HLA class I to inhibit NK cell cytotoxicity compared with
resting NK cells. Thus, ex vivo IL-15 stimulated NK cells could
be a strategy for treatment of MB patients, as has been reported
for other pediatric solid tumors (Cho et al., 2010). Although MB
survival has improved, a total cure is still not available. In this
study, average-risk patient had 55% chance of survival. How-
ever, metastatic disease at diagnosis, incomplete resections, and a
younger age at diagnosis had <40% chance survival. Furthermore,
MB relapse patients have a lower chance (<15%) to be successfully
treated. Thus, new strategies for the treatment of MB should be
developed.
In summary, this study provides fundamental insights into the
crosstalk between NK cells and MB tumors based on receptor-
ligand interactions. NK cells may play an important role in cyto-
toxicity of MB tumors and may therefore be a new target for future
medical therapies, especially in high-risk MB patients.
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